News
-
-
-
-
PRESS RELEASE
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
Immunic reports positive long-term data from phase 2 EMPhASIS Trial of Vidofludimus Calcium in relapsing-remitting multiple sclerosis, showing favorable safety & tolerability profile up to 5.5 years -
-
-
-
-
-
PRESS RELEASE
Correction of a release from 24/06/2025, 09:00 CET/CEST - Mountain Alliance aims to unlock new potential in defense tech
Mountain Alliance AG aims to unlock new potential in defense tech by investing in dual-use business models such as drone technology and cybersecurity. Strong defense expertise and dynamic market environment enhance portfolio diversification and exit capability